European Journal of Surgical Oncology
Volume 36, Issue 3 , Pages 224-229 , March 2010

The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease

  • O. Gojis

      Affiliations

    • Department of Gynaecology and Obstetrics, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10, 100 00, Czech Republic
    • Department of Pathology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10, 100 00, Czech Republic
    • Cancer Research UK Laboratories, Department of Oncology, Imperial College London-Hammersmith Campus, Du Cane Road, London W12 0NN, UK
    • ,
  • B. Rudraraju

      Affiliations

    • Cancer Research UK Laboratories, Department of Oncology, Imperial College London-Hammersmith Campus, Du Cane Road, London W12 0NN, UK
    • ,
  • C. Alifrangis

      Affiliations

    • Cancer Research UK Laboratories, Department of Oncology, Imperial College London-Hammersmith Campus, Du Cane Road, London W12 0NN, UK
    • ,
  • J. Krell

      Affiliations

    • Cancer Research UK Laboratories, Department of Oncology, Imperial College London-Hammersmith Campus, Du Cane Road, London W12 0NN, UK
    • ,
  • P. Libalova

      Affiliations

    • Department of Gynaecology and Obstetrics, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10, 100 00, Czech Republic
    • ,
  • C. Palmieri

      Affiliations

    • Cancer Research UK Laboratories, Department of Oncology, Imperial College London-Hammersmith Campus, Du Cane Road, London W12 0NN, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 20 8383 5828; fax: +44 20 8383 5830.

,Accepted 4 August 2009.

References 

  1. McKenna NJ, O'Malley BW. Minireview: nuclear receptor coactivators – an update. Endocrinology. 2002;143:2461–2465
  2. Mussi P, Yu C, O'Malley BW, et al. Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol. 2006;20:3105–3119
  3. Wu RC, Qin J, Yi P, et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic responses to multiple cellular signaling pathways. Mol Cell. 2004;15:937–949
  4. Torres-Arzayus MI, Font de Mora J, Yuan J, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell. 2004;6:263–274
  5. Xu J, Liao L, Ning G, et al. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci U S A. 2000;97:6379–6384
  6. Gnanapragasam VJ, Leung HY, Pulimood AS, et al. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer. 2001;85:1928–1936
  7. Zhou HJ, Yan J, Luo W, et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005;65:7976–7983
  8. Glaeser M, Floetotto T, Hanstein B, et al. Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. Horm Metab Res. 2001;33:121–126
  9. Kershah SM, Desouki MM, Koterba KL, et al. Expression of estrogen receptor coregulators in normal and malignant human endometrium. Gynecol Oncol. 2004;92:304–313
  10. Sakaguchi H, Fujimoto J, Sun WS, et al. Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers. J Steroid Biochem Mol Biol. 2007;104:237–240
  11. Balmer NN, Richer JK, Spoelstra NS, et al. Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: correlation with clinicopathologic parameters and biomarkers. Mod Pathol. 2006;19:1593–1605
  12. Fujita Y, Sakakura C, Shimomura K, et al. Chromosome arm 20q gains and other genomic alterations in esophageal squamous cell carcinoma, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Hepatogastroenterology. 2003;50:1857–1863
  13. Xu FP, Xie D, Wen JM, et al. SRC-3/AIB1 protein and gene amplification levels in human esophageal squamous cell carcinomas. Cancer Lett. 2007;245:69–74
  14. Al-azawi D, Ilroy MM, Kelly G, et al. Ets-2 and p160 proteins collaborate to regulate c-Myc inendocrine resistant breast cancer. Oncogene. 2008;27:3021–3031
  15. Qin L, Liao L, Redmond A, et al. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol. 2008;28:5937–5950
  16. Sakakura C, Hagiwara A, Yasuoka R, et al. Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int J Cancer. 2000;89:217–223
  17. Xie D, Sham JS, Zeng WF, et al. Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. Hum Pathol. 2005;36:777–783
  18. Henke RT, Haddad BR, Kim SE, et al. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res. 2004;10:6134–6142
  19. Wang Y, Wu MC, Sham JS, et al. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer. 2002;95:2346–2352
  20. Luo JH, Xie D, Liu MZ, et al. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival. Int Cancer. 2008;122:2554–2561
  21. Liu MZ, Xie D, Mai SJ, et al. Overexpression of AIB1 in nasopharyngeal carcinomas correlates closely with advanced tumor stage. Am J Clin Pathol. 2008;129:728–734
  22. Carroll RS, Brown M, Zhang J, et al. Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clin Cancer Res. 2000;6:3570–3575
  23. Shirazi SK, Bober MA, Coetzee GA. Polymorphic exonic CAG microsatellites in the gene amplified in breast cancer (AIB1 gene). Clin Genet. 1998;54:102–103
  24. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994;22:3183–3186
  25. Hsing AW, Chokkalingam AP, Gao YT, et al. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2002;11:337–341
  26. Platz EA, Giovannucci E, Brown M, et al. Amplified in breast cancer-1 glutamine repeat and prostate cancer risk. Prostate J. 2000;2:27–32
  27. Li AJ, Lerner DL, Gapuzan ME, et al. AIB1 polymorphisms predict aggressive ovarian cancer phenotype. Cancer Epidemiol Biomarkers Prev. 2005;14:2919–2922
  28. Harigopal M, Heymann J, Ghosh S, et al. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. Breast Cancer Res Treat. 2009;155:77–85
  29. Liao L, Chen X, Wang S, et al. Steroid receptor coactivator 3 maintains circulating insulin-like growth factor I (IGF-I) by controlling IGF-binding protein 3 expression. Mol Cell Biol. 2008;28:2460–2469
  30. Oh A, List HJ, Reiter R, et al. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res. 2004;64:8299–8308

PII: S0748-7983(09)00420-X

doi: 10.1016/j.ejso.2009.08.002

European Journal of Surgical Oncology
Volume 36, Issue 3 , Pages 224-229 , March 2010

Article Tools

* Image Usage & Resolution